Eton Pharmaceuticals Inc.
| NASDAQ: ETON | Healthcare / Biotechnology / USA |
| 3.67 | -0.0600 | -1.61% | Vol 22.15K | 1Y Perf 25.59% |
| Nov 29th, 2023 16:00 DELAYED |
| BID | 3.55 | ASK | 3.77 | ||
| Open | 3.69 | Previous Close | 3.73 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 10.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 172.48 | Finscreener Ranking | ★★★★+ 56.97 | |
| Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | ★+ 44.90 | |
| Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | ★★+ 47.48 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 36.87 | Earnings Rating | Strong Buy | |
| Market Cap | 94.17M | Earnings Date | 9th Nov 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.16 | |
| Beta | 1.24 |
Today's Price Range 3.553.75 | 52W Range 2.425.81 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.82% | ||
| 1 Month | -6.14% | ||
| 3 Months | -18.98% | ||
| 6 Months | -4.92% | ||
| 1 Year | 25.59% | ||
| 3 Years | -53.78% | ||
| 5 Years | -42.20% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -76.25 | |||
ROE last 12 Months | -66.27 | |||
ROA (5Y Avg) | -35.49 | |||
ROA last 12 Months | -36.96 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -44.58 | |||
Return on invested Capital Q | -15.58 | |||
Return on invested Capital Y | 4.45 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 3.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -8.80 | ||||
| 6.97 | ||||
| 6.03 | ||||
| - | ||||
| -98.00 | ||||
| -0.12 | ||||
| 6.97 | ||||
| 0.44 | ||||
| 70.92M | ||||
| Forward PE | 14.42 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.20 | ||||
| 3.50 | ||||
| 0.34 | ||||
| 0.57 | ||||
| -13.60 | ||||
| Leverage Ratio | 1.80 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 73.70 | ||||
| -45.40 | ||||
| -36.60 | ||||
| - | ||||
| -77.89 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 12.75M | ||||
| 0.50 | ||||
| 155.21 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.09 | 0.18 | 300.00 |
| Q01 2023 | -0.14 | -0.10 | 28.57 |
| Q04 2022 | 0.01 | 0.04 | 300.00 |
| Q03 2022 | -0.15 | -0.12 | 20.00 |
| Q02 2022 | 0.03 | -0.06 | -300.00 |
| Q01 2022 | -0.08 | -0.21 | -162.50 |
| Q04 2021 | 0.05 | 0.04 | -20.00 |
| Q03 2021 | -0.14 | -0.24 | -71.43 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | -0.07 | 0.00 | - |
| 12/2023 FY | -0.10 | 0.00 | - |
| 3/2024 QR | -0.02 | 0.00 | - |
| 12/2024 FY | 0.26 | 0.00 | - |
| Next Report Date | - |
| Estimated EPS Next Report | -0.10 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 22.15K |
| Shares Outstanding | 25.66K |
| Shares Float | 18.10M |
| Trades Count | 255 |
| Dollar Volume | 80.73K |
| Avg. Volume | 94.24K |
| Avg. Weekly Volume | 46.44K |
| Avg. Monthly Volume | 95.13K |
| Avg. Quarterly Volume | 141.14K |
Eton Pharmaceuticals Inc. (NASDAQ: ETON) stock closed at 3.67 per share at the end of the most recent trading day (a -1.61% change compared to the prior day closing price) with a volume of 22.15K shares and market capitalization of 94.16M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 17 people. Eton Pharmaceuticals Inc. CEO is Sean E. Brynjelsen.
The one-year performance of Eton Pharmaceuticals Inc. stock is 25.59%, while year-to-date (YTD) performance is 30.14%. ETON stock has a five-year performance of -42.2%. Its 52-week range is between 2.42 and 5.81, which gives ETON stock a 52-week price range ratio of 36.87%
Eton Pharmaceuticals Inc. currently has a PE ratio of -8.80, a price-to-book (PB) ratio of 6.97, a price-to-sale (PS) ratio of 6.03, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -36.96%, a ROC of -44.58% and a ROE of -66.27%. The company’s profit margin is -77.89%, its EBITDA margin is -36.60%, and its revenue ttm is $12.75 Million , which makes it $0.50 revenue per share.
Of the last four earnings reports from Eton Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.10 for the next earnings report. Eton Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Eton Pharmaceuticals Inc. is Strong Buy (1), with a target price of $10, which is +172.48% compared to the current price. The earnings rating for Eton Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Eton Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Eton Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.92, ATR14 : 0.24, CCI20 : -56.23, Chaikin Money Flow : -0.16, MACD : -0.13, Money Flow Index : 38.72, ROC : -18.98, RSI : 43.16, STOCH (14,3) : 22.76, STOCH RSI : 0.77, UO : 49.52, Williams %R : -77.24), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Eton Pharmaceuticals Inc. in the last 12-months were:
Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has a diversified pipeline of around eight product candidates in various stages of development.
CEO: Sean E. Brynjelsen
Telephone: +1 847 787-7361
Address: 21925 West Field Parkway, Deer Park 60010-7208, IL, US
Number of employees: 17
